{Reference Type}: Journal Article
{Title}: A Case of Polyserositis, Chylous Ascites and Hepatitis Induced by Immune Checkpoint Inhibitors.
{Author}: Castelli M;Betelli M;Valenti A;Merelli B;Loglio A;Viganò M;Benetti A;
{Journal}: Eur J Case Rep Intern Med
{Volume}: 11
{Issue}: 7
{Year}: 2024
暂无{DOI}: 10.12890/2024_004237
{Abstract}: We describe a rare case of polyserositis with chylous ascites following nivolumab therapy, highlighting the challenges in recognising and managing immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICPIs). Induced polyserositis and chylous ascites are very rare and require immunosuppressive treatment, with a variable response of high-dose IV steroids.<BR><B>CONCLUSIONS: </B>Oncological therapy with immune checkpoint inhibitors (ICPIs) is frequently associated with immune-related adverse events (irAEs) most involving cutaneous, gastrointestinal and pulmonary sites.